COVID-19-Related New-Onset and Exacerbated Skin Diseases
Investigators sought to evaluate the association between COVID-19 infection and persistent or new-onset rash following infection.
Investigators sought to evaluate the association between COVID-19 infection and persistent or new-onset rash following infection.
The findings from the largest review of cases of SSRI-related alopecia are provided
Researchers sought to investigate if post-infusion cooling time (PICT) could be reduced for patients treated with paclitaxel.
The approval was based on data from the phase 2/3 BRAVE-AA1 and phase 3 BRAVE-AA2 trials, which included adults with severe alopecia areata.
The first pill to treat adults with severe alopecia areata was approved by the U.S. Food and Drug Administration on Monday.
Patients with frontal fibrosing alopecia (FFA) do not need to have vitamin D levels tested as deficiency is unlikely tied to the pathogenesis of FFA.
The THRIVE-AA1 trial included adults aged 18 to 65 years with moderate to severe alopecia areata who had at least 50% scalp hair loss.
The prevalence and incidence of pediatric alopecia areata across various factors is investigated.
Literature on clinical studies and reports investigating the association between new-onset alopecia areata or the exacerbation of preexisting alopecia areata following infection with SARS-CoV-2 are reviewed.
The efficacy of ritlecitinib in treating patients with alopecia areata is assessed.